Eli Lilly’s Donanemab Set to Gain Breakthrough Therapy Designation in China
The Center for Drug Evaluation (CDE) website indicates that US-based Eli Lilly’s (NYSE: LLY) injectable...
Company
Changzhou Sifary Medtech Secures Series B Funding for Global Expansion
Changzhou Sifary Medical Technology Co., Ltd, a China-based platform for the globalization of oral medical...
Suzhou Thery’s Generic Nilotinib Approved by China’s NMPA
China-based Suzhou Thery Pharmaceutical Inc. has announced that the National Medical Products Administration (NMPA) has...
Zhifei Biological Products’ BCG Vaccine Filing Accepted by China’s NMPA
China-based Chongqing Zhifei Biological Products Co., Ltd (SHE: 300122) has announced that its clinical trial...
Yantai Dongcheng Pharma Gets FDA Go-Ahead for 177Lu-LNC1004 Clinical Trial
China-based Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675) has announced receiving approval from the...
VivaVision Biotech Partners with Everads Therapy for Retinal Disease Therapies
China’s VivaVision Biotech Inc. has announced a collaboration agreement with Israel-based Everads Therapy Ltd to...
Shenzhen-Based Rhegen Bio Raises RMB 100 Million in Pre-Series B Round
Shenzhen-based biotechnology company Rhegen Bio, specializing in mRNA technology, has reportedly raised RMB 100 million...
Hainan Poly Pharm’s Generic Ganciclovir Approved in Denmark
China-based Hainan Poly Pharm Co., Ltd (SHE: 300630) has announced receiving marketing approval from the...
Jacobio Pharma Doses First Patient in US Phase I/IIa Study for JAB-2485
China-based Jacobio Pharma (HKG: 1167) has announced that the first patient has been dosed in...
VACSERA in Talks with Sinovac to Establish Integrated Vaccine Plant
Egypt-based drug firm Holding Company for Biological Products and Vaccines (VACSERA) is reportedly in talks...
Eisai CEO Outlines Ambitions for Alzheimer’s Drug Leqembi After FDA Approval
Following US FDA approval for Japan-based Eisai Co., Ltd (TYO: 4523) and Biogen Inc’s (NASDAQ:...
Dizal’s Sunvozertinib and Golidocitinib Combo Gets NMPA Approval for Phase II Study
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has announced receiving approval from the National Medical...
Luye Pharma’s BA1301 Receives CDE Approval for Clinical Trials
China-based Luye Pharma Group (HKG: 2186) has announced receiving clinical trial approval from the Center...
HutchMed’s Sovleplenib Administered to First Patient in Phase II COVID-19 Study
On January 4, Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) administered its novel, investigational,...
Zai Lab and Novocure’s TTFields Device Shows Survival Benefit in Lung Cancer Study
Shares in Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) and its partner Novocure...
Salubris Pharmaceuticals Gains NMPA Approval for Phase I Study of SAL0133
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced receiving approval from the National...
Kactus Biosystems Partners with Bioheng for Cell Therapy Raw Materials
Shanghai-based Kactus Biosystems, a firm specializing in target proteins and raw enzymes, has announced a...
Immune-Onc Therapeutics Completes $131 Million Series B Financing
US-headquartered Immune-Onc Therapeutics, Inc. has announced the successful completion of a Series B financing round...
Henlius Completes First Dosing in Global Phase III Study for HanSiZhuang in LS-SCLC
Shanghai Henlius Biotech (HKG: 2696) has announced the completion of the first subject dosing in...
Singular Medical Secures Series B+ Funding for Cardiac Device Development
Singular Medical, a Suzhou-based maker of cardiac rhythm and heart failure devices, has reportedly raised...